NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Smith on Stocks:

The price of therapy based on comparison to other cancer therapies could be anywhere from $200,000 to $350,000 per year. Hence the US addressable market is in the range of $2.5 billion to $4.2 billion and the addressable market in the rest of the world would be as great.
https://smithonstocks.com/northwest-biotherapeutics-managements-decision-to-determine-survival-tail-for-dcvax-l-in-phase-3-trial-in-newly-diagnosed-glioblastoma-was-absolutely-the-right-move-nwbo-buy-0-25/

I hope, if this trial is successful and DCvax-l is approved, some kind of reimbursement mechanism will be available for all patients.

Reimbursement for Advanced Therapies is a hot issue in Europe and discussed last Tuesday at Phacilitate. I hope we learn something from this discussion in the coming weeks.

"Reimbursement Models for Advanced Therapies - how do you put a price on therapies that potentially transform lives?"
https://www.medcityhq.com/2019/07/24/atn-event-reimbursement-models-for-advanced-therapies/
https://twitter.com/eliaszapantis

And while some clever people were discussing the topic, something wonderful happened in Belgium! (in just two days)

September 18, 2019

Baby Pia: Almost 1m Belgians pay for life-saving drug.
https://www.bbc.com/news/world-europe-49739845?ocid=socialflow_twitter

Nearly 1 million Belgians donated money for a baby to receive lifesaving gene therapy.

The drug is not available in Europe, forcing the parents to travel to the U.S. and pay $2.1 million, the full price of the treatment. https://t.co/LSkq9PI8C3

— New York Daily News (@NYDailyNews) September 19, 2019